

Technology Advisory Interests Register

Topic: Upadacitinib for treating giant cell arteritis [ID6299]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David Meads	TAC Committee Member	Non-financial professional	University of Leeds has received funding from Abbvie for research in an unrelated area	18/11/2025	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Catherine Thompson	TAC Committee Member	Financial	I have received honoraria and payment for strategic advice from Roche (competitor), for other disease areas not related to this drug.	18/11/2025	It was agreed that Catherine's declaration would not prevent them from participating in discussions on this appraisal
Dr Fiona Coath	Expert	Direct – non-financial	Current chair of the BSR vasculitis and PMR SIG.	16/05/2025	It was agreed that Dr Coath's declaration would not prevent them from providing expert advice to the committee
Dr Sarah Mackie	Expert	Indirect	Consultancy/speaking activity during the last 12 months, for which all fees were paid to my employer, the University of Leeds, and for which I received no personal remuneration:	01/12/2025	It was agreed that Dr Mackie's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>AstraZeneca: virtual membership of TRANSFORM LUPUS working group (for whole of last 12 months and ongoing)</p> <p>UCB: virtual talk at Evolutions in Rheumatology meeting, 23 Nov 2024</p> <p>AbbVie: Advisory Board and meetings in connection with this: 2nd Dec 2024 onwards. In-person Advisory Board meeting occurred on 25th Feb, 2025. Further virtual consultancy meetings have also occurred (last: 28 Nov 2025) to follow up on matters discussed during the Advisory Board and therefore I have not specified an end-date for this activity.</p> <p>AbbVie: Speaking: delivered non promotional, in-person educational lecture at ARISE meeting (an educational meeting for rheumatology trainees and early career clinicians) on digital tools to record patient-reported outcomes in rheumatology, 6-7 Feb 2025.</p> <p>Novartis: Consultancy, 3rd June, 2025, virtual. Further consultancy meetings may occur in 2026.</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>AbbVie: Speaking: 7th Aug, 2025 to 19th Sept, 2025: Talk was delivered in-person on 18th Sept 2025 for AbbVie Satellite Symposium at the Irish Society for Rheumatology, I spoke on management of giant cell arteritis including discussion of recent published trial evidence.</p> <p>Please especially note the final indirect conflict. Although I personally have not and will not receive any payment for any of the above, travel and accommodation was paid by the company where this was necessary for performing the activity. I have indicated this by stating "in-person" where applicable. Otherwise, all activities were virtual and didn't require any travel or accommodation costs to be met.</p>		